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Abstract 
 
Background 
There may be reluctance to perform coronary angiography in kidney transplant patients due 
to perceived risk of iodinated contrast, despite an increased risk of cardiovascular disease 
compared with the general population. 
Aim 
We sought to determine if renal transplant function was adversely affected within 7, 30 and 
180 days of coronary angiography. 
Methods   
Renal transplant recipients undergoing coronary angiography in a single centre (01/2006–
02/2018) were identified retrospectively. Baseline and highest SCr within 7, 30 and 180 days 
of coronary angiography were extracted from the electronic patient record. Rise in creatinine 
>26 micromol/l was considered significant (equivalent to Acute Kidney Injury (AKI) Network 
criteria stage 1 AKI) and case note review performed to determine circumstance of renal 
decline.  
Results   
There were 127 coronary angiographies conducted in 90 patients: 67.7% were male and 
mean age was 58.0 (+10.1) years. There was AKI within 7 days in 18.9% cases, but SCr 
returned to baseline within 7 days or there was an alternative explanation for AKI in 83.3% of 
these. In the remaining 4 cases, there was progressive decline in renal transplant function. 
In the absence of critical illness, no patient required dialysis or extended hospital stay for 
contrast-associated AKI.  
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Conclusions   
In this cohort of renal transplant recipients undergoing coronary angiography, AKI occurred 
in a minority of cases, and in more than 95% of such cases this effect was transient, with 
progressive renal decline a rare and predictable event. Renal transplant should not be 
regarded as a contraindication to coronary angiography. 
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Background and aim 
Renal impairment is an independent risk factor for type 1 myocardial infarction or cardiac 
death at 1 year, independent of other known risk factors for cardiovascular disease1.  
Cardiovascular disease remains common after renal transplantation, with an incidence of 3-5 
times that of the general population2.  Death from cardiovascular disease in the renal 
transplant population has reduced in recent years, but still accounts for around 22% of 
deaths in prevalent renal transplant recipients, and around 26% of deaths in those aged <65 
years3.   
Patients with renal transplant are deemed to be at higher risk of acute kidney injury (AKI) 
after receiving iodinated contrast4, along with those with chronic kidney disease (CKD; 
particularly estimated glomerular filtration rate (eGFR) <40ml/min/1.73m2), heart failure, age 
>75 years, hypovolaemia, high- or repeated-dose intravenous contrast or intra-arterial 
contrast administration4.   
Large, population-level analyses have recently been reassuring regarding the overall risk of 
acute kidney injury after intravenous contrast in those with normal renal function6 and with 
chronic kidney disease7.  A meta-analysis of the existing data suggests that acute kidney 
injury after contrast exposure is common in kidney transplant patients8.  Despite the elevated 
level of risk of cardiovascular disease in the renal transplant population, there may be 
reluctance to perform coronary angiography because of perceived risk of contrast-induced 
nephropathy.  This risk must be weighed against the potential increased risk of death with a 
functioning graft in those with significant and sub-optimally treated coronary artery disease.  
We sought to determine the impact of iodinated contrast on renal transplant function on an 
individual case basis in renal transplant recipients undergoing coronary angiography for any 
indication. 
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Methods 
We retrospectively included all renal transplant recipients from a single centre undergoing 
coronary angiography from January 2006 to February 2018 inclusive.  Baseline demographic 
and biochemical data were extracted from the electronic patients record, including: sex, age 
at angiography (years), serum creatinine (SCr – micromol/l) values at baseline, within 7 
days, 30 days and 180 days following coronary angiography, time since transplant, time 
since first renal replacement therapy and date of death.  We reviewed case notes for 
additional clinical data, including heart failure status and whether patients had an active 
prescription of ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB) at time of 
coronary angiography, and date and type of cardiac surgery up to 180 days after coronary 
angiography.  eGFR was calculated from SCr using the CKD-EPI equation9.  Patients were 
not routinely administered IV fluid peri-procedure, but some received intravenous fluid before 
or after coronary angiography at the discretion of the responsible physician.  Coronary 
angiography reports and images and electronic patient records were reviewed for indication 
and procedure conducted at angiography and route taken for angiography (transradial 
versus transfemoral).  Ethical approval was not required on the basis that this was analysis 
of routine clinical data.  Data were fully anonymised and Caldicott Guardian approval was 
granted by the information governance manager of NHS Greater Glasgow and Clyde.   
We defined baseline SCr as the nearest SCr prior to date of coronary angiography.  In 31 
cases when the SCr was not available within 48 hours of angiography, the most recent 
available SCr was checked to ensure it was in keeping with SCr over the 3 months prior to 
coronary angiography: if it was not, the average SCr over 3 months prior to coronary 
angiography was considered the baseline SCr.  The highest SCr within 7 days of coronary 
angiography was extracted and compared with baseline values.  Acute kidney injury was 
defined as a rise in SCr >26 micromol/l (equivalent to Acute Kidney Injury Network criteria 
stage 1 AKI)10 within 7 days of coronary angiography.  In cases when there was AKI after 
coronary angiography, electronic case notes were reviewed for cause of creatinine rise.  In 
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the absence of a clear alternative explanation for rise in SCr, AKI was attributed to iodinated 
contrast.  To explore longer-term effects on renal transplant function, we extracted highest 
SCr values within 30 and 180 days of coronary angiography.  When no creatinine values 
were available within 30 days, the next available SCr after 30 days was extracted. 
Data are presented as mean + standard deviation for normally distributed data; median and 
interquartile range for non-normally distributed data. Comparisons between groups were 
made using Student’s t test, Mann-Whitney test or Chi-square test as appropriate.  Data 
were collated and analysed using Microsoft Excel 2016 MSO and stats and pastecs 
packages for R statistical software (R Studio (version 1.0.136) available at http://www.R-
project.org and distributed under the GNU (http://www.gnu.org) General Public License).  
Data are presented according to STROBE reporting guidelines for observational studies. 
 
Results 
There were 127 coronary angiographies conducted in 90 renal transplant patients over 12.2 
years.  There was a male preponderance of 67.7%.  The mean age was 58.0 years (SD 
10.2) and the median time since transplant was 6.2 years (IQR 2.5-16.1).  Further baseline 
demographics can be found in Table I. The most common indications for coronary 
angiography were angina (27.6%), non-ST elevation myocardial infarction (23.6%) and 
staged percutaneous coronary intervention procedures (16.5%) (Table II).  Diagnostic 
angiography was conducted in 59.1%; angioplasty or stenting in 40.9% (Table III). 
The incidence of AKI was 18.9% (n=24/127; median rise 52 micromol/l, range 28-163).  
Those who had AKI within 7 days were younger (53.6 vs 59.0 years, p=0.01) with lower GFR 
(29.6 vs 44.7 ml/min/1.73m2, p=0.003).  There were no significant differences between time 
since renal transplant or duration of end-stage renal disease (Table I).  There was a higher 
proportion of hypertension (95.8 vs 92.2%, p<0.001) but lower proportion of diabetes (29.2 
vs 35.9%, p<0.001) in the group who had AKI (Table I).   
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SCr values were available within 7 days for 98 patients.  In 56 instances when there was any 
rise in creatinine within 7 days, the median maximum creatinine rise was 23 micromol/l 
(range 2-163), and median time to maximum creatinine was 3 days (IQR 1-4).  Figure 1 
shows the maximum change in serum creatinine for individual coronary angiography events 
(from baseline and within 7, 30 and 180 days).   
The overall rate of confirmed AKI within 7 days was more common in those with GFR <30 
ml/min/1.73m2 (Chi-square p=0.01) but not significantly more common in those with heart 
failure, who were prescribed ACEi or ARB, who were undergoing percutaneous coronary 
intervention compared with diagnostic angiography alone or when undergoing angiography 
via femoral versus radial route (Table III).  Amongst those with confirmed AKI within 7 days, 
58.3% were conducted via transradial route; 41.7% via transfemoral route.   
SCr returned to baseline within 7 days or there was an alternative explanation for rise in SCr 
in 20/24 cases (Table IV).  In the remaining 4 cases with AKI attributed to administration of 
contrast (3% overall), there was known severe and progressive renal transplant dysfunction 
(baseline SCr median 354 micromol/l, range 274-464).   
Amongst those with no available SCr within 7 days (n=29/127), none had a persistent rise in 
SCr extracted from days 7-30 post angiography, or the next available SCr after 30 days 
(median rise in SCr 3 micromol/l, range -31 - 25).  In the absence of critical illness at time of 
coronary angiography, no patient required dialysis or extended hospital stay for contrast-
associated acute kidney injury.  
There were 2 patients who underwent cardiac surgery (coronary artery bypass grafting, open 
valve replacement/repair or combined surgery) within 30 days of coronary angiography.  
Neither patient showed deterioration in renal transplant function within 180 days.  Of 6 
patients undergoing cardiac surgery between 30 and 180 days after coronary angiography, 
two patients demonstrated progressive renal transplant dysfunction within 180 days 
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(baseline and 180 day change in SCr: 153 + 58 micromol/l; 144 + 48 micromol/l 
respectively).   
Discussion 
In this cohort of prevalent renal transplant recipients, there was a low rate of clinically 
significant AKI within 7 days of coronary angiography, with very few cases of AKI that could 
be attributed to administration of iodinated contrast, and the majority had only a transient rise 
in SCr.   
We acknowledge some limitations in the findings of this study.  First, this is a single-centre 
study and includes a relatively small cohort of patients.  Second, coronary angiography 
necessarily requires administration of iodinated contrast, and therefore there is no control 
group available for comparison.  Third, though some physicians reported efforts to minimise 
contrast exposure, we can make no comment on the volume or type of contrast administered 
– which may impact on risk of AKI8 - as this was inconsistently recorded.  Fourth, there was 
inconsistent measurement of SCr within 7 days of coronary angiography and we cannot be 
sure to have captured all episodes of AKI in this period.  Nevertheless, in the group of 
patients who did not have available SCr within 7 days, there was no change to transplant 
function beyond 7 days compared with baseline.  The strengths of this study lie in the 
individual case analysis, including qualifying the cause and degree of acute kidney injury.  
Based on a population-level assessment, we estimate 18.9% rate of AKI after coronary 
angiography, but 7.9% rate of contrast-induced AKI and only 3.1% associated with 6-month 
decline in transplant function, all of whom already had progressive deterioration in transplant 
function.   
Contrast-induced nephropathy is thought to be a form of acute tubular injury.  The 
mechanism is not completely understood but is likely to be multifactorial11.  There remains 
significant anxiety in administering iodinated contrast to high-risk patients including renal 
transplant recipients.  In a survey of 421 radiologists (2000 were offered participation), fewer 
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than 30% state that they would frequently administer iodinated contrast for CT scanning to 
patients with renal transplant and 11% reported they would never use contrast for renal 
transplant patients12.  Amongst radiologists who would consider using contrast, the average 
cut-off serum creatinine was 145 micromol/l (equivalent to eGFR >30ml/min in most cases), 
but varied between 132-177 micromol/l for the majority of respondents12.   
AKI is common after coronary angiography: Tsai et al estimated that over a quarter of high-
risk patients (including those with renal transplant) undergoing coronary angiography suffer 
post-procedure acute kidney injury13.  We found a greater proportion of AKI in those with 
lower GFR.  In a large, propensity score-matched analysis, McDonald et al7 showed similar 
significant increase in AKI with decreasing GFR (n=12 508, p<0.0001) but did not find any 
association with contrast exposure.  In a follow-up study to address groups with CKD 3 (GFR 
30-59 ml/min/1.73m2) and CKD 4/5 (GFR <30 ml/min/1.73m2) specifically14, AKI, dialysis 
requirement and mortality were not significantly higher in those who received iodianted 
contrast.  These data cannot be directly extrapolated to renal transplant patients, who may 
have additional risk factors compared to those with CKD, including calcineurin-based 
immunosuppression and possibly greater duration and severity of diabetes and 
cardiovascular disease.  In renal transplant patients, Haider et al reported no impact of 
baseline serum creatinine on risk of contrast-associated AKI15, albeit in a population with 
better baseline transplant function (GFR >70ml/min/1.73m2) than our own cohort (42 
ml/min/1.73m2).  In a meta-analysis of renal transplant patients, incidence of AKI varied 
according to the procedure: 16% for cardiac catheterisation, 10% for other angiography and 
6% for contrast-enhanced CT scan8, though no study reported a persisting requirement for 
dialysis relating to iodinated contrast8.  
Strategies to reduce the risk of contrast-associated AKI have been implemented in recent 
years.  Peri-procedure intravenous hydration is evidence-based in reducing the frequency 
and severity of AKI after contrast exposure16,17, though not routinely administered in our unit.  
There has been a move away from high-osmolar ionic contrast agents to lower-osmolar 
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agents and European Society of Cardiology guidelines now recommend reduction or 
restriction of contrast volumes in high-risk patients undergoing coronary angiography18: both 
are likely to contribute to lower AKI rate8,19.  The choice of approach for coronary 
angiography also impacts risk of AKI.  The AKI-MATRIX study randomised 8210 patients to 
trans-radial or trans-femoral approach for coronary angiography in a 1:1 ratio20.  Those 
undergoing transradial coronary angiography had significantly fewer AKI episodes (15.4% 
vs. 17.4%; p=0.018) compared with those undergoing transfemoral angiography20.  
Approximately 80.5% of coronary angiographies are conducted via the transradial route in 
the UK 21,22; over 90% coronary angiographies in Glasgow are transradial23.  Proportionately 
fewer patients had transradial coronary angiography in our cohort (64.6%): lack of radial 
access due to previous fistula creation was the predominant explanation.   
Conclusion 
Consistent with previous reports, our findings are reassuring that risk of contrast-associated 
AKI is low, including in this cohort with sub-optimal kidney transplant function, without routine 
administration of intravenous hydration peri-procedure and undergoing proportionately more 
transfemoral angiographies than the general UK population.  There is a clinically significant 
rise in SCr in only a very small minority of cases and does not substantially or permanently 
affect renal transplant function.  Given the burden of cardiovascular disease in this patient 
group, renal transplant should not be regarded as a contra-indication to coronary 
angiography. 
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Tables 
Table I 
 
Baseline data 
No AKI (7 
days) 
(n=103) 
AKI (7 days) 
(n=24) 
All  
(n=127) 
P-
value 
Male (%) 67.0 70.8 67.7 0.72 
Age (years) 59.0 (10.3) 53.6 (8.8) 58.0 (10.2) 0.01 
Hypertension (%) 92.2 95.8 92.9 <0.001 
Diabetes (%) 35.9 29.2 34.6 <0.001 
Baseline SCr (micromol/l) 146 (107-209) 264 (161-429) 255 (110-220) <0.001 
Baseline eGFR 
(ml/min/1.73m2) 
44.7 (21.5) 29.6 (21.2) 41.9 (22.2) 0.003 
Time since transplant (years) 5.7 (2.5-16.0) 8.5 (2.9-16.4) 6.2 (2.5-16.1) 0.97 
Time since first RRT (years) 12.10 (6.3-23.3) 15.6 (8.1 - 26.2) 13.4 (6.8-25.0) 0.45 
Dead at end follow-up (%) 16.5 33.3 19.7 0.11 
Dialysis at end follow-up (%) 4.9 0.1 6.3 0.36 
Baseline demographics of included patients.  Data are represented as mean (SD) or median 
(IQR) for normally and non-normally distributed data respectively.   
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Table II 
Indication n (%) 
(127 total) 
Angina 35 (27.6) 
Non-STEMI 30 (23.6) 
Staged PCI 21 (16.5) 
Pre-operative valve replacement 18 (14.2) 
STEMI 14 (11.0) 
Investigation of heart failure 9 (7.1) 
Indications for coronary angiography.  PCI: percutaneous coronary intervention.  STEMI: ST-
elevation myocardial infarction. 
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Table III 
 No AKI within 7 days (%) AKI within 7 days (%) Total 
eGFR CATEGORY 
eGFR >60 ml/min/1.73m2 28 (90.3) 3 (9.7) 31 
eGFR 30-60 ml/min/1.73m2 44 (88.0) 6 (12.0) 50 
eGFR >30 ml/min/1.73m2 31 (67.4) 15 (32.6) 46 
Rate of AKI according to GFR category: Chi-square p=0.01 
POST-TRANSPLANT HEART FAILURE 
No heart failure 76 (82.6) 15 (16.3) 92 
Heart failure 27 (75.0) 9 (25.0) 36 
Rate of AKI according to heart failure status: Chi-square p=0.27 
ACEi OR ARB PRESCRIBED AT TIME OF CORONARY ANGIOGRAPHY 
No ACE or ARB 67 (79.8) 17 (19.5) 84 
ACE or ARB 36 (83.7) 7 (16.3) 43 
Rate of AKI according to prescription of ACE or ARB: Chi-square p=0.59 
PROCEDURE CONDUCTED AT ANGIOGRAPHY 
Diagnostic angiography 65 (86.7) 10 (13.3) 75 
Diagnostic angiography & PCI 26 (70.3) 11 (29.7) 37 
PCI only 12 (80.0) 3 (20.0) 15 
Rate of AKI after diagnostic angiography vs intervention: Chi-square p=0.11 
ROUTE OF ANGIOGRAPHY (TRANSRADIAL VS. TRANSFEMORAL) 
Transradial 68 (82.9) 14 (17.1) 82 
Transfemoral 35 (77.8) 10 (22.2) 45 
Rate of AKI according to route of angiography: Chi-square p=0.48 
TOTAL 103 (81.1) 24 (18.9) 127 
Rate of acute kidney injury after coronary angiography according to estimated glomerular 
filtration rate (eGFR), history of post-transplant heart failure, active prescription of ACE 
inhibitor (ACEi) or angiotensin receptor blocker (ARB) at time of coronary angiography, 
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procedure conducted at coronary angiography or route of coronary angiography. AKI: acute 
kidney injury.  PCI: percutaneous coronary intervention (balloon angioplasty or stenting). 
  
19 
 
Table IV 
 
Cause of deterioration 
n=  
(24 
total) 
Peak SCr rise 
within 7 days: 
median (range) 
Peak SCr 
within 30 days:  
median (range) 
SCr difference 
at 180 days: 
median (range) 
RELATED TO CONTRAST 
Genuine rise:  
Back to baseline within 7 days 
6 43 (36 – 45) 43 (36 – 45) -2 (-173 – 50) 
Genuine rise: 
Later decline in renal function 
4 47 (28 – 85) 76 (42 – 140) 167 (59 – 172) 
UNRELATED TO CONTRAST 
SCr at angiography lower than 
usual baseline  
4 35 (28 – 138) 39 (33 – 138) 25 (15 – 39) 
Drug-induced AKI 1 30 30 na* 
Usual variability in baseline SCr 1 33 33 16 
Requiring dialysis for AKI 4 93 (58 – 129) 139 (58 – 195) 174** 
Critical illness  4 72 (59 – 163) 72 (59 – 163) na*** 
 
Cause of rise in creatinine >26 micromol/l within 7, 30 and 180 days of coronary 
angiography on review of electronic case records.  SCr: serum creatinine. AKI: acute kidney 
injury.  * no SCr available at 180 days.  ** single SCr value available at 180 days.  *** all 
patients died within 180 days of coronary angiography. 
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Figure legend 
Figure 1:  Bar chart to represent serum creatinine (SCr) kinetics for individual coronary 
angiography events at baseline and within 7, 30 and 180 days.  Cases are ordered from 
lowest to highest baseline SCr.  Positive or negative changes in SCr are represented in 
shaded bars going up or down from the baseline value of SCr respectively.   
